Clinical Trial

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-03-27; most recent amendment 2025-10-27.
Status change: Recruiting → Active, Not Recruiting 2025-10-27
Trial Details
NCT Number NCT06342960
Lead Sponsor Kyverna Therapeutics
Conditions Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV
Enrollment 2 participants
Start Date 2022-12-01
Primary Completion 2028-10 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-29